Omnicell (OMCL) Q4 2024 earnings summary

Executive summary

• Exceeded 2024 bookings guidance, driven by strong demand for connected devices, XT upgrades, and successful product launches such as XT Amplify, Central Med Automation Service, and OmniSphere, with a robust $1.201 billion backlog supporting 2025 revenue planning.

• Returned to year-over-year revenue growth in Q4 2024, with improved execution, strong free cash flows, and a focus on long-term value creation through digital transformation and SaaS expansion.

• Strategic focus for 2025 includes accelerating recurring revenue growth, achieving consistent GAAP profitability, and innovation in medication management.

• Recognized leader in medication management with a 30-year track record and strong presence in over half of the top 300 U.S. health systems.

• Strong balance sheet and capital allocation discipline expected to enable sustainable and profitable growth.

Financial highlights

• Q4 2024 total revenue was $307 million, up $24 million sequentially and 19% year-over-year; product revenue was $182 million, up $24 million sequentially and $37 million year-over-year; service revenue was $125 million, up $1 million sequentially and $11 million year-over-year.

• Q4 2024 non-GAAP gross margin was 47.4% (up 380bps YoY); GAAP EPS was $0.34 (vs. $0.19 prior quarter, -$0.32 prior year); non-GAAP EPS was $0.60 (up $0.27 YoY); non-GAAP EBITDA was $46 million, up 96% YoY.

• Full year 2024 revenue was $1.112 billion, down 3% year-over-year; product revenue $631 million, services revenue $482 million.

• Full year 2024 non-GAAP EPS was $1.71 (down $0.20 year-over-year); non-GAAP EBITDA was $136 million, slightly down from $138 million in 2023 but above guidance.

• Cash and equivalents at year-end were $369 million, down from $571 million prior quarter due to convertible note transactions; free cash flow in Q4 was $43 million.

Outlook and guidance

• 2025 product bookings expected at $500–$550 million; ARR expected at $610–$630 million (up from $580 million in 2024).

• 2025 total revenue guidance is $1.105–$1.155 billion (midpoint 2% growth); product revenue flat, services revenue to grow, led by SaaS and expert services.

• 2025 non-GAAP EBITDA expected at $140–$155 million; non-GAAP EPS $1.65–$1.85, with a $0.20 headwind from reduced interest income.

• Q1 2025 revenue guidance: $255–$265 million; product revenue $137–$142 million; services $118–$123 million; non-GAAP EPS $0.15–$0.25.

• SaaS and Expert Services revenues projected at $260–$270 million for 2025.